Literature DB >> 20093281

Metformin suppresses hepatic gluconeogenesis through induction of SIRT1 and GCN5.

Paul W Caton1, Nanda K Nayuni, Julius Kieswich, Noorafza Q Khan, Muhammed M Yaqoob, Roger Corder.   

Abstract

Abnormal elevation of hepatic gluconeogenesis is central to the onset of hyperglycaemia in patients with type 2 diabetes mellitus (T2DM). Metformin corrects hyperglycaemia through inhibition of gluconeogenesis, but its mechanism of action is yet to be fully described. SIRT1 and GCN5 (listed as KAT2A in the MGI Database) have recently been identified as regulators of gluconeogenic gene expression through modulation of levels and activity of the coactivators cAMP-response element binding protein-regulated transcription coactivator 2 (TORC2 or CRTC2 as listed in the MGI Database) and peroxisome proliferator-activated receptor-gamma coactivator-1alpha (PGC1alpha or PPARGC1A as listed in the MGI Database). We report that in db/db mice, metformin (250 mg/kg per day; 7 days) increases hepatic levels of GCN5 protein and mRNA compared with the untreated db/db mice, as well as increases levels of SIRT1 protein and activity relative to controls and untreated db/db mice. These changes were associated with reduced TORC2 protein level and decreased gene expression and activation of the PGC1alpha gene target phosphoenolpyruvate carboxykinase, and lower plasma glucose and insulin. Inhibition of SIRT1 partially blocked the effects of metformin on gluconeogenesis. SIRT1 was increased through an AMP-activated protein kinase-mediated increase in gene expression of nicotinamide phosphoribosyltransferase, the rate-limiting enzyme of the salvage pathway for NAD(+). Moreover, levels of GCN5 were dramatically reduced in db/db mice compared with the controls. This indicates that loss of GCN5-mediated inhibition of gluconeogenesis appears to constitute a major mechanism for the onset of abnormally elevated hepatic glucose production in db/db mice. In conclusion, induction of GCN5 and SIRT1 potentially represents a critical mechanism of action of metformin. In addition, these data identify induction of hepatic GCN5 as a potential therapeutic strategy for treatment of T2DM.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20093281     DOI: 10.1677/JOE-09-0345

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  65 in total

1.  Locating the source of hyperglycemia: liver versus muscle.

Authors:  Haoyong Yu; Dequan Zhou; Weiping Jia; ZengKui Guo
Journal:  J Diabetes       Date:  2012-03       Impact factor: 4.006

2.  Regulation of glycolytic enzyme phosphoglycerate mutase-1 by Sirt1 protein-mediated deacetylation.

Authors:  William C Hallows; Wei Yu; John M Denu
Journal:  J Biol Chem       Date:  2011-12-07       Impact factor: 5.157

Review 3.  Clinical relevance of epigenetics in the onset and management of type 2 diabetes mellitus.

Authors:  Linda Sommese; Alberto Zullo; Francesco Paolo Mancini; Rossella Fabbricini; Andrea Soricelli; Claudio Napoli
Journal:  Epigenetics       Date:  2017-01-06       Impact factor: 4.528

4.  A novel inverse relationship between metformin-triggered AMPK-SIRT1 signaling and p53 protein abundance in high glucose-exposed HepG2 cells.

Authors:  Lauren E Nelson; Rudy J Valentine; José M Cacicedo; Marie-Soleil Gauthier; Yasuo Ido; Neil B Ruderman
Journal:  Am J Physiol Cell Physiol       Date:  2012-02-29       Impact factor: 4.249

5.  Pank1 deletion in leptin-deficient mice reduces hyperglycaemia and hyperinsulinaemia and modifies global metabolism without affecting insulin resistance.

Authors:  Roberta Leonardi; Charles O Rock; Suzanne Jackowski
Journal:  Diabetologia       Date:  2014-04-30       Impact factor: 10.122

6.  Metformin treatment status and abdominal aortic aneurysm disease progression.

Authors:  Naoki Fujimura; Jiang Xiong; Ellen B Kettler; Haojun Xuan; Keith J Glover; Matthew W Mell; Baohui Xu; Ronald L Dalman
Journal:  J Vasc Surg       Date:  2016-04-19       Impact factor: 4.268

7.  Sirtuin biology and relevance to diabetes treatment.

Authors:  X Charlie Dong
Journal:  Diabetes Manag (Lond)       Date:  2012-05

Review 8.  Enzymatic and nonenzymatic protein acetylations control glycolysis process in liver diseases.

Authors:  Juan Li; Tongxin Wang; Jun Xia; Weilei Yao; Feiruo Huang
Journal:  FASEB J       Date:  2019-08-01       Impact factor: 5.191

9.  Metformin alleviates hepatosteatosis by restoring SIRT1-mediated autophagy induction via an AMP-activated protein kinase-independent pathway.

Authors:  Young Mi Song; Yong-ho Lee; Ji-Won Kim; Dong-Sik Ham; Eun-Seok Kang; Bong Soo Cha; Hyun Chul Lee; Byung-Wan Lee
Journal:  Autophagy       Date:  2015       Impact factor: 16.016

10.  Metformin induces PGC-1α expression and selectively affects hepatic PGC-1α functions.

Authors:  Sanna-Mari Aatsinki; Marcin Buler; Henriikka Salomäki; Markku Koulu; Petr Pavek; Jukka Hakkola
Journal:  Br J Pharmacol       Date:  2014-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.